LTZ 231
Alternative Names: LTZ-231Latest Information Update: 02 Sep 2023
At a glance
- Originator LTZ Therapeutics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Macrophage stimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Acute myeloid leukaemia
Most Recent Events
- 31 May 2023 Early research in Acute myeloid leukaemia in USA (unspecified route) (LTZ Therapeutics pipeline, June 2023)